The Pfizer New Haven Clinical Research Unit is conducting a clinical trial of an oral study drug for certain types of breast cancer. This study will look at the effects of single doses of the study drug given as different types of tablets either with or without food.
Worldwide, breast cancer is the most common invasive cancer, with more than 2.2 million people impacted annually. Metastatic breast cancer, the most advanced stage of breast cancer in which the cancer has spread to other parts of the body (i.e., organs, bones), remains an incurable disease.
We are committed to supporting patients by developing innovative medicines that have the potential to help people with various types of breast cancer. Learn how you can join our efforts as a healthy volunteer below.
Who may participate
As a healthy clinical trial participant, you are at the center of drug discoveries that could help patients around the world.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18+ years
Sex
All sexes
Referral bonus
Up to $225
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility 3 separate times for 8 overnights each, for a total of 24 nights. Each stay is called a “period” and on the first morning of each period you will receive a single oral dose of the study medication as one or more tablets to swallow. The doses may be given with or without food.
There will be about 14 days between the doses in periods 1 and 2, and about 60 days between the doses in periods 2 and 3. You are still considered “on study” during these times, meaning you cannot participate in another clinical trial during this window. All of the study dates will be reviewed with you at your screening appointment to ensure the study schedule works for you.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
Required overnight stays
3 admissions of 8 nights each (24 total)
Long-term follow up
1 phone call
How long is this study?
About 114 days
Compensation
Up to $10,900 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
The PCRU Loyalty Program has arrived!
Our new Loyalty Program offers unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.